Amendments to the Claims

This claim listing will replace all prior versions of claims and claim listings in the application:

1. (Original) A compound structurally represented by Formula I



(I)

or pharmaceutically acceptable salts thereof wherein:

G^1 is $-CH_2-$, or $-CH_2-CH_2-$,

G^2 is $-CH_2-$, or $-C(O)-$,

or G^1 and G^2 taken together combine to form $-CH=CH-$ or $-CH_2-CH=CH-$,

Y is

$-OCH_2CH_2N$-piperidinyl,

$-OCH_2CH_2CH_2N$-piperidinyl,

$-OCH_2CH_2N$-pyrrolidinyl,

$-OCH_2CH_2CH_2N$- pyrrolidinyl,

X is H, $-COR^3$, $-CH_2R^4$, $-SO_2R^5$,

R^3 is

$-(C_1-C_8)$ alkyl, optionally substituted with 1 to 3 halogens,

$-(C_3-C_8)$ cycloalkyl, optionally substituted with 1 to 3 halogens,

$-O(C_1-C_8)$ alkyl, optionally substituted with 1 to 3 halogens,



, wherein R^6 is -(C_1-C_6) alkyl, or –COO-(C_1-C_6) alkyl,

-Furanyl,

-Thienyl,

-NH-phenyl,

-NH-(C_1-C_4)alkyl-phenyl,

-NH-(C_1-C_8) alkyl, optionally substituted with 1 to 4 halogens,

-NH-(C_3-C_8) cycloalkyl, optionally substituted once or twice with halogens,

-CH_2-Pyridinyl,

-CH_2N (C_1-C_6) alkyl (C_1-C_6) alkyl,

-CH_2N-phenyl,

R^4 is

-(C_1-C_8) alkyl, optionally substituted with 1 to 4 halogens,

-(C_3-C_8) cycloalkyl,

-(C_1-C_8) alkyl-NH_2,

-(C_1-C_4) alkyl –phenyl,

-CH_2N-phenyl,

-phenyl-O-(C_1-C_4) alkyl –phenyl,

-(C_1-C_4) alkyl-O-(C_1-C_4) alkyl-phenyl,

-CH_2NCO_2-(C_1-C_6) alkyl,

-Phenyl,

-Thienyl,

-Furanyl,

-Imidazolyl,

-Naphthyl,



, wherein R^6 is -(C_1-C_6) alkyl, or -COO-(C_1-C_6) alkyl, -Biphenyl, and

R^5 is

-Phenyl,

-(C_1-C_4) alkyl,

-(C_1-C_4) alkyl –phenyl.

2. (Original) The compound of claim 1, wherein R^1 and R^2 cyclize to form a 5-membered ring.

3. (Original) The compound of claim 1, wherein R^1 and R^2 cyclize to form a 6-membered ring.

4. (Original) The compound of claim 2 wherein Y is in the 5 position.

5. (Original) The compound of claim 3 wherein Y is in the 6 position.

6. (Original) The compound of claim 4 wherein X is CO.

7. (Original) The compound of claim 1, selected from the group consisting of:

Example Number	Structure
1	
2	
3	

4	
5	
6	
7	
8	
9	

10	
11	
12	
13	
14	

15	
16	
17	
18	
19	
20	

21	
22	
23	
24	
25	
26	

27	
28	
29	
30	
31	

32	
33	
34	
35	
36	

37	
38	
39	
40	
41	

42	
43	
44	
45	

46	
47	
48	
49	
50	

51	 Chiral
52	 Chiral
53	
54	
55	

56	
57	Chiral 
58	
59	Chiral 
60	Chiral 

61	
62	
63	
64	

or a pharmaceutically acceptable salt or solvate thereof.

8. (Currently amended) A pharmaceutical composition which comprises a compound of ~~any of~~ claims ~~1-7~~ 1 or 7 and a pharmaceutically acceptable carrier.

9. (Cancelled)

10. (Cancelled)

11. (Cancelled)

12. (Currently amended) A method for treatment or prevention of obesity which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of ~~any of~~ Claims ~~1-7~~ 1 or 7.

13. (Original) The method of Claim 12 wherein the antagonist is a pharmaceutical composition of claim 8.

14. (Currently amended) A method for treatment or prevention of a cognitive disorder ~~or disease in which inhibition of the histamine H3 receptor has a beneficial effect~~ which comprises administering to a subject in need of such treatment or prevention an effective amount of a compound of ~~any of~~ claims ~~1-7~~ 1 or 7.

15. (New) The method of Claim 15 wherein the antagonist is a pharmaceutical composition of claim 8.